Modulation of specific and selective central/ hypothalamic HIF in obesity can function as a protective mechanism to reduce the negative impact of hypothalamic dysfunction thus, placing tissue specific HIF-1 activation as a potential therapeutic target for the pharmacological management of obesity and type 2 diabetes. This evidence concerns the gene HIF1A and obesity due to melanocortin 4 receptor deficiency.